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In this edition of Pediatric Dermatology Samimi and
Siegfried report the interesting and provocative case of a
9-year-oldgirlwithhypocomplementemic systemic lupus
erythematosus and severe nephritis. Over an approxi-
mate 3-week time span this very ill patient was treated
withsevendierentagents including intravenousandoral
corticosteroids.Within 2±3weeks (andwhile on steroids)
she developed a fever and a widespread eruption invol-
ving her face, trunk, and the mucous membranes of her
eyes,mouth,andvulva. Intravenouscefuroximewas then
added.At that timeadermatologyconsultant suggesteda
diagnosis of bullous lupus erythematosus or Stevens±
Johnson syndrome (SJS). The skin biopsy favored SJS
and a direct immuno¯uorescence study was negative.
Furosemide was discontinued as ``the most likely cause''
but the disease progressed over the next 2 days. At this
pointa4-daycourseof intravenous immunoglobin(IVIg)
(750 mg/kg/day) and the reinstitution of intravenous
methylprednisolone 1 mg/kg every 12 hours was begun.
Hydroxychloroquine and cefuroxime were discontinued
and replaced by vancomycin and cefazidime. Her con-
dition continued to deteriorate for the next 3 days with
critical care management including skin debridement,
transfusion of blood and albumin, and intubation with
mechanical ventilation. Gradual improvement began
4daysafter startingIVIgandthepatientwasdischarged3
weeks later.
There are several important new points regarding
severe erythema multiforme (EM) that are illustrated by
this case report andother recent publications.This article
will comment on the practical importance for the
involved clinician of increased susceptibility to EM in
high-risk patient groups (disease predisposition), genetic
predisposition, and the role of drugs in causing and
treating SJS/toxic epidermal necrolysis (TEN).
HIGH-RISK PATIENT GROUPS
The discussion section of Samimi and Siegfried's manu-
script points out that there are certain groups at
somewhat higher risk for the development of SJS,
speci®cally focusing on systemic lupus erythematosus
(SLE). Patients with HIV infection and malignancies
treated with radiation also appear somewhat more
susceptible to SJS and TEN (1). Another recent publi-
cation investigates the role of human herpesvirus 6 in
these severe adverse drug reactions (ADRs) (2). Unfor-
tunately the dermatologist, althoughaware that a patient
is ``high risk,'' cannotusuallydefer therapybecauseof the
serious nature of the underlying illness, so not much
practical advantage is gained here except heightened
suspicion. Although it is commonly suggested that drugs
be used with ``caution'' in these situations, I am not
certain what this entails since I presume that all
medications are administered in this manner. Perhaps a
more appropriate caveat would be to treat all new
eruptions as if they are life threatening and proceed
directly to avoidance and aggressive therapy.
GENETIC PREDISPOSITION
It is becoming increasingly apparent that many patients
who have severe ADRs such as SJS/TEN do so because
of their metabolic predisposition. Wolkenstein et al (3)
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studied the reaction of lymphocytes from patients with
severe cutaneous ADRs to metabolites of sulfonamides
and anticonvulsants, family members of those aected,
and a group of nonaected, unrelated controls. In all
situations, aected patients' lymphocytes suered more
toxicity when exposed to metabolites of the suspected
drug thandid thoseof controls.Familymembersof those
who suered ADRs also had higher reaction rates to
these metabolites, suggesting that these reactions were in
some way genetically determined by inherited metabo-
lism. These abnormalities have been linked to the
cytochrome P-450 system and certain human leukocyte
antigen (HLA) subtypes.
Anticonvulsant hypersensitivity syndromes may be
related to individuals' inability to properly metabolize
arene oxide by-products of these medications, the actual
immunologic reaction being not to the medication itself
but to a metabolic degradation product. The immuno-
logic mechanism has been recently described in detail by
Sullivan and Shear (4).
Is there some practical way to screen users of themost
likely drug causes of EM for this predisposition? In
addition to the method described in the preceding para-
graphs, there are numerous other mechanisms that can
be used for in vitro testing for ADRs as outlined by
Rieder (5): in vitro challenge, radioallergosorbent test
(RAST), basophil degranulation, determination of spe-
ci®c antibodies, determination of immune mediators,
and study of enzymic pathways. Unfortunately these
modalities areusuallynot commercially available andare
impractical for pretreatment evaluation. Even though
the risk may be increased many fold in these groups of
patients, systemic therapy with high-risk drugs is fre-
quently necessary.While having a higher risk, the rate of
ADR remains low in ``slow metabolizers'' and there is
still no practical way to avoid EM in this group of
patients. Therefore a clinician should also have a higher
degree of concern for drug eruptions in these high-risk
groups and act accordingly, with close monitoring and
early drug discontinuation.
NEW INFORMATION REGARDING
CAUSATIVE DRUGS AND THERAPY
The discussion section of Samimi and Siegfried's article
also reviews the controversy regarding systemic steroids
and their eect on EM. They mention the recent
knowledge that corticosteroids may on occasion be a
culprit drug (6).
The increased risk for the use of corticosteroids was
originally reported by Roujeau et al (6), who noted ``no
explanation is apparent for the high risk we observed
with recently initiated corticosteroid therapy.'' After
correcting for concomitant disease and drug use, the
authors concluded ``the relative risk remains signi®cantly
elevated when subjects with these factors were excluded''
(6). It is not clear from this information whether physi-
cians treating patients who developed EM while receiv-
ing steroids should have discontinued these medicines or
increased the dose.
Amoreusefulmethodof suspecting thepresenceof an
ADR is the ``length of exposure'' rule. Roujeau et al (6)
have attempted to de®ne the risk of developing SJS or
TEN during the short- and long-term use of a large
number of medications. They noted greatly increased
risks for patients whose medication had been recently
started (less than 2 months duration) with most of the
commonly suspected agents, including anticonvulsants,
antibiotics, and antiarthritic drugs. However, they noted
that a signi®cant risk still existed for the long-term use
of both phenobarbital and valproic acid even after
2 months, so it isn't enough to withdraw the most
recently introduced agents when the SJS appears.
The clinician is then left as the primary detective to
determine which drug from the most likely of causative
agents also ®ts the time use rule. That is, agents which
have been in use for many months are highly unlikely to
have causedEM.Thosewho®t in the 7- to 21-day period
are most likely and those within a 2-month window are
still considered possible causes and should be discontin-
ued. The most dicult aspect of this decision making
is illustrated by the patient described in this case
reportÐmultiple medications used for a variety of rea-
sons including lupus and presumed infection. Sometimes
you simply have to toss them all out and start over again.
This, however, is a very dicult therapeutic choice and
usually isn't attempted unless the clinician has no clear
alternative.
The accurate determination of the causative agent
mayhave a substantial in¯uence on survival regardless of
the patient's underlying medical condition. Garcia-
Doval et al (7) recently published a retrospective review
suggesting that early discontinuation of some drugs is
associated with a substantial decrease in mortality. They
noted that for drugs with a short half-life (less than 24
hours), early withdrawal (within 1 day of the onset of
blistering)was associatedwith a 5%mortality.When the
drug was stopped after that point the death rate was
26%. These eects were apparent even when adjustment
had been made for variables such as maximum surface
area blistered or other associated underlying diseases.
Such bene®ts were not noted for patients who were
taking drugs with a half-life longer than 24 hours.
The study of Garcia-Doval et al (7) raises many
questions. Several drugs which are common causes of
SJS/TEN such as phenytoin were not included in the
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list of causative agents. Corticosteroids were also not
among the drugs that were considered causative in this
series. In addition, half-life was determined from a 1985
edition of Goodman and Gilman, The Pharmacological
Basis of Therapeutics (8). It wasn't explained why a
more current source such as the Physician's Desk
Reference wasn't utilized.
In an editorial accompanying the Garcia-Doval et al
publication, Robert Stern (9) noted the pros and cons of
discontinuing all non-life-sustaining medications versus
only the suspected one, correctly commenting that many
medicines will be unnecessarily withdrawn. This is very
dicult to do in hospitalized patients who have major
organ involvement due to other diseases. Not discussed
by either theGarcia-Doval group or Stern is the fact that
certain drugs are metabolized more slowly in the older
patient or in those with diseased organs (e.g., declining
renal function) or through modi®cation by other agents
that induce changes in the cytochrome P-450 system. In
these situations a clinician has no clear choiceÐpick the
most likely drug, discontinue it, and monitor closely.
My approach has usually been to try to identify the
most likely culprit based on reputation, introduction
during the preceding 1- to 4-week period, and prior his-
tory of allergy. I amnot surewhat to doabout the patient
who is already on corticosteroids when the EM begins,
although I usually continue them for a short period
of time and increase the dose if early in the course of
SJS/TEN.
I think the picture is clearerwhen only a single agent is
used but much more complex when the patient is hos-
pitalized with signi®cant underlying medical problems
and is using multiple drugs.
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